Therapeutic Asset Ratings
153 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
[18F]MODAG-009
Parkinson Disease
MODAG GmbH
Early P1
C
(34)
NOS
Parkinson Disease
University of Pennsylvania
Early P1
C
(34)
Yohimbine
Parkinson Disease
Hospices Civils de Lyon
Early P1
C
(34)
(2S)-1-FLUORO-3-((2-(6-METHYL-3-PYRIDYL)-6-QUINOLYL)OXY)PROPAN-2-OL
Parkinson Disease
Anhui Provincial Hospital
D
(28)
AMMONIA N-13
Parkinson Disease
National Institute of Neurological Disorders and Stroke (NINDS)
D
(28)
APIGENINE
Parkinson Disease
Jinnah Postgraduate Medical Centre
N/A
D
(28)
Carboplatin
Parkinson Disease
University of Colorado, Denver
N/A
D
(28)
CARFENTANYL
Parkinson Disease
Hospices Civils de Lyon
N/A
D
(28)
Chamomile
Parkinson Disease
Jinnah Postgraduate Medical Centre
N/A
D
(28)
CIMBI-36
Parkinson Disease
University of Exeter
D
(28)
CLOSTRIDIUM BUTYRICUM MIYAIRI 588
Parkinson Disease
Kaohsiung Medical University Chung-Ho Memorial Hospital
N/A
D
(28)
Cobalamin
Parkinson Disease
Babujinaya Cela
N/A
D
(28)
Cyclophosphamide
Parkinson Disease
Oregon Health and Science University
N/A
D
(28)
DASB
Parkinson Disease
University of Exeter
D
(28)
Epirubicin
Parkinson Disease
University of Colorado, Denver
N/A
D
(28)
ER-176
Parkinson Disease
Mayo Clinic
D
(28)
GLUCOSE, ANHYDROUS
Parkinson Disease
University Hospital Schleswig-Holstein
N/A
D
(28)
LECANEMAB
Parkinson Disease
Yonsei University
N/A
D
(28)
LIDOCAINE
Parkinson Disease
Babujinaya Cela
N/A
D
(28)
LIPOPOLYSACCHARIDE
Parkinson Disease
University of Exeter
D
(28)
Pembrolizumab
Parkinson Disease
University of Colorado, Denver
N/A
D
(28)
ROPIVACAINE
Parkinson Disease
Changhai Hospital
N/A
D
(28)
Saffron
Parkinson Disease
Jinnah Postgraduate Medical Centre
N/A
D
(28)
Sl-Apo
Parkinson Disease
Bial - Portela C S.A.
D
(28)
TZ-3321
Parkinson Disease
Washington University School of Medicine
D
(28)
Showing 126 to 150 of 153 assets
Previous
Page 6 of 7
Next